![Frontiers | Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study Frontiers | Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study](https://www.frontiersin.org/files/Articles/824831/fpsyt-13-824831-HTML/image_m/fpsyt-13-824831-g001.jpg)
Frontiers | Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
![Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial | American Journal of Psychiatry Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/appi.ajp.2015.15050648/asset/images/medium/appi.ajp.2015.15050648f2.gif)
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial | American Journal of Psychiatry
![Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis - The Lancet Psychiatry Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis - The Lancet Psychiatry](https://www.thelancet.com/cms/asset/74cb18e5-9dab-4e11-a41e-c686d89be094/gr2.jpg)
Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis - The Lancet Psychiatry
![Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial | American Journal of Psychiatry Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/appi.ajp.2015.15050648/asset/images/medium/appi.ajp.2015.15050648f1.gif)